Moleculin Biotech (LTS:0K2H) Receivables Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K2H Moleculin Biotech Inc LTS:0K2H
18 GF Score
Price $0.76
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Moleculin Biotech's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Moleculin Biotech's average Accounts Receivable for the three months ended in Jun. 2026 was $0.00 Mil.

Moleculin Biotech  (LTS:0K2H) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Moleculin Biotech Receivables Turnover Related Terms

Moleculin Biotech Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Receivables Turnover Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Moleculin Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LTS:0K2H vs BCLI, ANEB, ASBP: Receivables Turnover Comparison

For the Biotechnology subindustry, Moleculin Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moleculin Biotech Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Receivables Turnover falls into.


LTS:0K2H
18GF Score
Moleculin Biotech Inc LTS:0K2H
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Moleculin Biotech's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=0 / (( + ) / 1 )
=0 / 0
=N/A

Moleculin Biotech's Receivables Turnover for the quarter that ended in Jun. 2026 is calculated as

Receivables Turnover (Q: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2026 ) / ((Accounts Receivable (Q: Mar. 2026 ) + Accounts Receivable (Q: Jun. 2026 )) / count )
=0 / (( + ) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Business Description

Other Exchanges MBRX:USA
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
18GF Score

Get the complete analysis for LTS:0K2H

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price